ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth

AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance.

Read more at prnewswire.com